The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|February 27, 2026
Familiar Faces at Winter Clinical Miami 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Subscribing to an eNewsletter creates a predictable pipeline of curated conference insights for later review.
- Following relevant social channels accelerates access to newly released updates and discussion.
As Winter Clinical kicks off in Aventura, Florida, scroll through and find some faces familiar to Dermatology Times who are presenting at the meeting.
Advertisement
To stay up-to-date with the latest conference insights, sign up to receive our
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement